4-amino-5-fluoro-3-(5-methyl-1H-benzimidazol-2-yl)quinolin-2(1H)-one | 668423-56-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-amino-5-fluoro-3-(5-methyl-1H-benzimidazol-2-yl)quinolin-2(1H)-one
• 英文别名: 4-amino-5-fluoro-3-(6-methyl-1H-benzimidazol-2-yl)-1H-quinolin-2-one
• CAS: 668423-56-1
• 化学式: C₁₇H₁₃FN₄O
• 分子量: 308.315
• InChiKey: LIIVNFHORPNIKW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  83.8
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• TREATMENT OF MELANOMA
  申请人：Heise Carla C.

  公开号：US20100086518A1

  公开（公告）日：2010-04-08

  Methods of treating melanoma include administering a compound of Structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt or the tautomer, or a mixture thereof to a subject. The compound, tautomer, salt of the compound, salt of the tautomer, or mixture thereof may be used to prepare medicaments for treating metastatic cancer. The variable A has the values defined herein.

  治疗黑色素瘤的方法包括向受试者施用结构I的化合物、化合物的互变异构体、化合物的药用可接受盐、互变异构体的药用可接受盐或两者的混合物。该化合物、互变异构体、化合物的盐、互变异构体的盐或两者的混合物可用于制备治疗转移性癌症的药物。变量A具有定义在此处的值。
• TREATMENT OF METASTASIZED TUMORS
  申请人：Lopes de Menezes Daniel

  公开号：US20100173873A1

  公开（公告）日：2010-07-08

  Methods of treating metastatic cancer such as metastasized tumors include administering a compound of Structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt or the tautomer, or a mixture thereof to a subject. The compound, tautomer, salt of the compound, salt of the tautomer, or mixture thereof may be used to prepare medicaments for treating metastatic cancer. The variable A has the values defined herein.

  治疗转移性癌症（如转移性肿瘤）的方法包括向受试者施用结构I的化合物、化合物的互变异构体、化合物的药学上可接受的盐、互变异构体的药学上可接受的盐或其混合物。该化合物、互变异构体、化合物的盐、互变异构体的盐或其混合物可用于制备治疗转移性癌症的药物。变量A具有在此处定义的值。
• Benzimidazole quinolinones and uses thereof
  申请人：Novartis Vaccines and Diagnostics, Inc.

  公开号：EP2573079A2

  公开（公告）日：2013-03-27

  Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes.

  提供了抑制各种酶和治疗各种病症的方法，包括向受试者施用结构 I 或 IB 的化合物、其药学上可接受的盐、其同系物或同系物的药学上可接受的盐。具有结构 I 和 IB 的化合物具有以下结构，并具有本文所述的变量。此类化合物可用于制备抑制各种酶和治疗由此类酶介导的疾病的药物。
• Pharmaceutically acceptable salts of quinolinone compounds and their medical use
  申请人：Novartis Vaccines and Diagnostics, Inc.

  公开号：EP2762475A1

  公开（公告）日：2014-08-06

  A salt of a compound of Formula I or a tautomer of the compound, wherein Formula I has the following structure and R1-R9 and R12-R14 are as defined herein

  式 I 化合物的盐或该化合物的同系物，其中式 I 具有如下结构，R1-R9 和 R12-R14 如本文所定义